Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034. doi: 10.1016/j.jacc.2017.12.048. Review.

PMID:
29495982
2.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

Circulation. 2018 Feb 27;137(9):961-972. doi: 10.1161/CIRCULATIONAHA.117.033502. Review.

PMID:
29483172
3.

Financial management of a large multisite randomized clinical trial.

Sheffet AJ, Flaxman L, Tom M, Hughes SE, Longbottom ME, Howard VJ, Marler JR, Brott TG; CREST Investigators.

Int J Stroke. 2014 Aug;9(6):811-3. doi: 10.1111/ijs.12259. Epub 2014 Mar 24.

4.

Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.

Lindblad AS, Manukyan Z, Purohit-Sheth T, Gensler G, Okwesili P, Meeker-O'Connell A, Ball L, Marler JR.

Clin Trials. 2014 Apr;11(2):205-17. doi: 10.1177/1740774513508028. Epub 2013 Dec 2.

PMID:
24296321
5.

A strategic plan to accelerate development of acute stroke treatments.

Marler JR.

Ann N Y Acad Sci. 2012 Sep;1268:152-6. doi: 10.1111/j.1749-6632.2012.06714.x. Review.

PMID:
22994235
6.

National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods.

Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S.

Clin Trials. 2012 Jun;9(3):322-9. doi: 10.1177/1740774512438980. Epub 2012 Feb 27.

7.

Secondary analysis of clinical trials--a cautionary note.

Marler JR.

Prog Cardiovasc Dis. 2012 Jan-Feb;54(4):335-7. doi: 10.1016/j.pcad.2011.09.006. Review.

PMID:
22226000
8.

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G.

Lancet. 2010 May 15;375(9727):1695-703. doi: 10.1016/S0140-6736(10)60491-6.

PMID:
20472172
9.

Neuroprotection trials in Parkinson's disease: systematic review.

Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR.

Mov Disord. 2009 Apr 15;24(5):647-54. doi: 10.1002/mds.22432. Review.

PMID:
19117366
10.

Stroke outcome in clinical trial patients deriving from different countries.

Ali M, Atula S, Bath PM, Grotta J, Hacke W, Lyden P, Marler JR, Sacco RL, Lees KR; VISTA Investigators.

Stroke. 2009 Jan;40(1):35-40. doi: 10.1161/STROKEAHA.108.518035. Epub 2008 Oct 16.

PMID:
18927457
11.

NINDS clinical trials in stroke: lessons learned and future directions.

Marler JR.

Stroke. 2007 Dec;38(12):3302-7. Epub 2007 Oct 25.

PMID:
17962606
12.

Acute medical therapy.

Lyden PD, Marler JR.

J Stroke Cerebrovasc Dis. 1999 May-Jun;8(3):139-45. No abstract available.

PMID:
17895156
13.

The Virtual International Stroke Trials Archive.

Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, Fisher M, Gregson BA, Grotta J, Hacke W, Hennerici MG, Hommel M, Kaste M, Marler JR, Sacco RL, Teal P, Wahlgren NG, Warach S, Weir CJ, Lees KR.

Stroke. 2007 Jun;38(6):1905-10. Epub 2007 Apr 19.

PMID:
17446430
14.

Should stroke patients with mild or improving symptoms receive tissue plasminogen activator therapy?

Marler JR.

Nat Clin Pract Neurol. 2006 Jul;2(7):354-5. No abstract available.

PMID:
16932581
15.

National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards.

Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG.

Stroke. 2006 Sep;37(9):2220-41. Epub 2006 Aug 17. Erratum in: Stroke. 2007 Mar;38(3):1118. Wallin, Anders [added].

PMID:
16917086
16.

Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition.

Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O'Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD; Brain Attack Coalition.

Stroke. 2005 Jul;36(7):1597-616. Epub 2005 Jun 16.

PMID:
15961715
17.

Data and safety monitoring in clinical research: a National Institute of Neurologic Disorders and Stroke perspective.

Conwit RA, Hart RG, Moy CS, Marler JR.

Ann Emerg Med. 2005 Apr;45(4):388-92. Review.

PMID:
15795717
18.

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators.

Lancet. 2004 Mar 6;363(9411):768-74.

PMID:
15016487
19.

Medicine. Stroke--tPA and the clinic.

Marler JR, Goldstein LB.

Science. 2003 Sep 19;301(5640):1677.

PMID:
14500967
20.

Lessons from the Stroke Prevention in Atrial Fibrillation trials.

Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR; Stroke Prevention in Atrial Fibrillation Investigators.

Ann Intern Med. 2003 May 20;138(10):831-8. Review.

PMID:
12755555
21.

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.

Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR.

Neurology. 2003 Apr 22;60(8):1234-40. Review.

PMID:
12707423
22.

Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association.

Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ; Stroke Council of the American Stroke Association.

Stroke. 2003 Apr;34(4):1056-83. No abstract available.

PMID:
12677087
23.

NINDS-sponsored clinical trials in stroke: past, present, and future.

Marler JR.

Stroke. 2002 Jan;33(1):311-2. No abstract available.

PMID:
11779932
24.

Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.

Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

JAMA. 2001 Dec 12;286(22):2830-8.

PMID:
11735758
25.

Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.

Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, Fagan SC, Kothari R, Levine SR, Marler JR, Lyden PD, Haley EC Jr, Brott T, Grotta JC; NINDS t-PA Stroke Study Group.

Ann Neurol. 2001 Jun;49(6):736-44.

PMID:
11409425
26.

EMD & acute stroke response.

Sinclair R, Marler JR.

JEMS. 2000 Oct;25(10):28-9. No abstract available.

PMID:
11141763
27.

Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.

Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP.

Neurology. 2000 Dec 12;55(11):1649-55.

PMID:
11113218
28.

Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.

Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, Brott TG, Grotta J, Tilley BC, Marler JR, Frankel M.

Stroke. 2000 Oct;31(10):2335-41.

PMID:
11022060
29.

Recommendations for the establishment of primary stroke centers. Brain Attack Coalition.

Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, Starke RD, Todd HW, Viste KM, Girgus M, Shephard T, Emr M, Shwayder P, Walker MD.

JAMA. 2000 Jun 21;283(23):3102-9. Review.

PMID:
10865305
30.

Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group.

Woo D, Broderick JP, Kothari RU, Lu M, Brott T, Lyden PD, Marler JR, Grotta JC.

Stroke. 1999 Nov;30(11):2355-9.

PMID:
10548670
31.

Thrombolysis in acute ischemic stroke: controlled trials and clinical experience.

Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, Donnan G, Heiss WD, Wahlgren NG, Spranger M, Boysen G, Marler JR.

Neurology. 1999;53(7 Suppl 4):S3-14. Review.

PMID:
10532643
32.

Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy.

Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D.

Stroke. 1999 Aug;30(8):1528-33.

PMID:
10436095
33.

Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.

Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T.

N Engl J Med. 1999 Jun 10;340(23):1781-7.

34.

Early stroke diagnosis saves time.

Marler JR.

Ann Emerg Med. 1999 Apr;33(4):450-1. No abstract available.

PMID:
10092725
35.

Hypertension and its treatment in the NINDS rt-PA Stroke Trial.

Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC.

Stroke. 1998 Aug;29(8):1504-9.

PMID:
9707184
36.

Progress in acute stroke research.

Marler JR, Walker MD.

Stroke. 1998 Aug;29(8):1491-2. No abstract available.

PMID:
9707179
37.

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.

Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD.

Neurology. 1998 Apr;50(4):883-90.

PMID:
9566367
38.

American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Acute interventions.

Pessin MS, Adams HP Jr, Adams RJ, Fisher M, Furlan AJ, Hacke W, Haley EC Jr, Hazinski MF, Helgason CM, Higashida RT, Koroshetz W, Marler JR, Ornato JP.

Stroke. 1997 Jul;28(7):1518-21. No abstract available.

PMID:
9227709
39.

Intravenous thrombolysis for acute stroke.

Lyden PD, Grotta JC, Levine SR, Marler JR, Frankel MR, Brott TG.

Neurology. 1997 Jul;49(1):14-20. Review. No abstract available.

PMID:
9222164
40.

Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association.

Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W.

Circulation. 1996 Sep 1;94(5):1167-74. No abstract available.

PMID:
8790069
41.

Guidelines for Thrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association.

Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W.

Stroke. 1996 Sep;27(9):1711-8. No abstract available.

PMID:
8784157
42.

Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients.

Barsan WG, Brott TG, Broderick JP, Haley EC Jr, Levy DE, Marler JR.

Stroke. 1994 Nov;25(11):2132-7.

PMID:
7974533
43.

Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.

Adams HP Jr, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA, et al.

Circulation. 1994 Sep;90(3):1588-601. No abstract available.

PMID:
8087974
44.

Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.

Adams HP Jr, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA, et al.

Stroke. 1994 Sep;25(9):1901-14. No abstract available.

PMID:
8073477
45.

Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.

Levy DE, Brott TG, Haley EC Jr, Marler JR, Sheppard GL, Barsan W, Broderick JP.

Stroke. 1994 Feb;25(2):291-7.

PMID:
8303734
46.

Time of hospital presentation in patients with acute stroke.

Barsan WG, Brott TG, Broderick JP, Haley EC, Levy DE, Marler JR.

Arch Intern Med. 1993 Nov 22;153(22):2558-61.

PMID:
7598755
47.

Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.

Haley EC Jr, Brott TG, Sheppard GL, Barsan W, Broderick J, Marler JR, Kongable GL, Spilker J, Massey S, Hansen CA, et al.

Stroke. 1993 Jul;24(7):1000-4.

PMID:
8322373
48.

Circadian rhythmicity of stroke onset. Intracerebral and subarachnoid hemorrhage.

Sloan MA, Price TR, Foulkes MA, Marler JR, Mohr JP, Hier DB, Wolf PA, Caplan LR.

Stroke. 1992 Oct;23(10):1420-6.

PMID:
1412578
49.

Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.

Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR.

Stroke. 1992 May;23(5):641-5.

PMID:
1579959
50.

Circadian variation in onset of acute ischemic stroke.

Marsh EE 3rd, Biller J, Adams HP Jr, Marler JR, Hulbert JR, Love BB, Gordon DL.

Arch Neurol. 1990 Nov;47(11):1178-80.

PMID:
2241613

Supplemental Content

Loading ...
Support Center